Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now

Raymond Niaura, William G. Shadel, Kathleen Morrow, Karen Tashima, Timothy Flanigan, David Abrams

Research output: Contribution to journalArticle

Abstract

Treatments for persons who are infected with human immunodeficiency virus (HIV) or who have developed AIDS have advanced to the point where death is no longer the inevitable outcome of diagnosis. Combination antiretroviral therapy has made HIV infection less of a terminal condition and more of a medically manageable chronic disease. Thus, efforts to improve the health status and quality of life of HIV-infected persons have become one of the highest treatment priorities for the next decade. Cigarette smoking is highly prevalent among HIV-infected persons, and quitting smoking would greatly improve the health status of these individuals. However, to date, no studies have evaluated the efficacy of a smoking-cessation intervention specifically tailored to this population. This article reviews the evidence and rationale for advancing smoking-cessation treatments specifically tailored to the needs of HIV-infected persons and provides recommendations for future treatment studies.

Original languageEnglish (US)
Pages (from-to)808-812
Number of pages5
JournalClinical Infectious Diseases
Volume31
Issue number3
DOIs
StatePublished - 2000

Fingerprint

Virus Diseases
Smoking Cessation
Acquired Immunodeficiency Syndrome
HIV
Health Status
Smoking
Withholding Treatment
Therapeutics
Chronic Disease
Quality of Life
Population

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Human immunodeficiency virus infection, AIDS, and smoking cessation : The time is now. / Niaura, Raymond; Shadel, William G.; Morrow, Kathleen; Tashima, Karen; Flanigan, Timothy; Abrams, David.

In: Clinical Infectious Diseases, Vol. 31, No. 3, 2000, p. 808-812.

Research output: Contribution to journalArticle

Niaura, Raymond ; Shadel, William G. ; Morrow, Kathleen ; Tashima, Karen ; Flanigan, Timothy ; Abrams, David. / Human immunodeficiency virus infection, AIDS, and smoking cessation : The time is now. In: Clinical Infectious Diseases. 2000 ; Vol. 31, No. 3. pp. 808-812.
@article{ecdb85efbbf1464684269bf3ad78412e,
title = "Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now",
abstract = "Treatments for persons who are infected with human immunodeficiency virus (HIV) or who have developed AIDS have advanced to the point where death is no longer the inevitable outcome of diagnosis. Combination antiretroviral therapy has made HIV infection less of a terminal condition and more of a medically manageable chronic disease. Thus, efforts to improve the health status and quality of life of HIV-infected persons have become one of the highest treatment priorities for the next decade. Cigarette smoking is highly prevalent among HIV-infected persons, and quitting smoking would greatly improve the health status of these individuals. However, to date, no studies have evaluated the efficacy of a smoking-cessation intervention specifically tailored to this population. This article reviews the evidence and rationale for advancing smoking-cessation treatments specifically tailored to the needs of HIV-infected persons and provides recommendations for future treatment studies.",
author = "Raymond Niaura and Shadel, {William G.} and Kathleen Morrow and Karen Tashima and Timothy Flanigan and David Abrams",
year = "2000",
doi = "10.1086/314048",
language = "English (US)",
volume = "31",
pages = "808--812",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Human immunodeficiency virus infection, AIDS, and smoking cessation

T2 - The time is now

AU - Niaura, Raymond

AU - Shadel, William G.

AU - Morrow, Kathleen

AU - Tashima, Karen

AU - Flanigan, Timothy

AU - Abrams, David

PY - 2000

Y1 - 2000

N2 - Treatments for persons who are infected with human immunodeficiency virus (HIV) or who have developed AIDS have advanced to the point where death is no longer the inevitable outcome of diagnosis. Combination antiretroviral therapy has made HIV infection less of a terminal condition and more of a medically manageable chronic disease. Thus, efforts to improve the health status and quality of life of HIV-infected persons have become one of the highest treatment priorities for the next decade. Cigarette smoking is highly prevalent among HIV-infected persons, and quitting smoking would greatly improve the health status of these individuals. However, to date, no studies have evaluated the efficacy of a smoking-cessation intervention specifically tailored to this population. This article reviews the evidence and rationale for advancing smoking-cessation treatments specifically tailored to the needs of HIV-infected persons and provides recommendations for future treatment studies.

AB - Treatments for persons who are infected with human immunodeficiency virus (HIV) or who have developed AIDS have advanced to the point where death is no longer the inevitable outcome of diagnosis. Combination antiretroviral therapy has made HIV infection less of a terminal condition and more of a medically manageable chronic disease. Thus, efforts to improve the health status and quality of life of HIV-infected persons have become one of the highest treatment priorities for the next decade. Cigarette smoking is highly prevalent among HIV-infected persons, and quitting smoking would greatly improve the health status of these individuals. However, to date, no studies have evaluated the efficacy of a smoking-cessation intervention specifically tailored to this population. This article reviews the evidence and rationale for advancing smoking-cessation treatments specifically tailored to the needs of HIV-infected persons and provides recommendations for future treatment studies.

UR - http://www.scopus.com/inward/record.url?scp=0034458294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034458294&partnerID=8YFLogxK

U2 - 10.1086/314048

DO - 10.1086/314048

M3 - Article

C2 - 11017836

AN - SCOPUS:0034458294

VL - 31

SP - 808

EP - 812

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -